AVBP

Arrivent Biopharma Stock Analysis

AI Rating

Good
  • Quality4/10
  • Growth↓ 4/10
  • Value↑ 5/10
Arrivent Biopharma sales and earnings growth
AVBP Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -68.75%
  • FCF Y/Y↓ -128.72%
Arrivent Biopharma gross and profit margin trends
AVBP Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 0.00%
Arrivent Biopharma net debt vs free cash flow
AVBP Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Arrivent Biopharma stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗